The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule.
Perlini
Stefano
S
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001713:Biphenyl Compounds / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000187:drug effects / Q000378:metabolism; D003900:Desoxycorticosterone; D004359:Drug Therapy, Combination; D005355:Fibrosis / Q000188:drug therapy / Q000473:pathology; D006331:Heart Diseases / Q000188:drug therapy / Q000473:pathology; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D007674:Kidney Diseases / Q000188:drug therapy / Q000473:pathology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D015260:Neprilysin / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D063065:Organophosphonates / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D013841:Thiazepines / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D015815:Cell Adhesion Molecules; D063065:Organophosphonates; D011725:Pyridines; D013841:Thiazepines; C086165:CGS 25462; C106266:omapatrilat; D003900:Desoxycorticosterone; D008666:Metalloendopeptidases; D015260:Neprilysin